No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Devices
Nova Eye Medical Limited specializes in the creation, advancement, distribution, marketing, sale, and servicing of surgical equipment dedicated to treating glaucoma. Its diverse product line features iTrack, a surgical system engineered to decrease intraocular pressure (IOP) in adult patients with open-angle glaucoma, and iTrack Advance, an innovative system promoting natural ocular fluid drainage. Furthermore, the company provides Molteno3, a glaucoma drainage device for individuals suffering from severe or intricate forms of the condition, alongside 2RT, a proprietary laser technology employed to address early to intermediate stages of age-related macular degeneration. With a presence spanning Australia, the United States, Europe, the Asia Pacific, and other international markets, the company, originally established in 1985 as Ellex Medical Lasers Limited, officially became Nova Eye Medical Limited in July 2020. Its corporate headquarters are situated in Kent Town, Australia.
nova-eye.comNo one on the platform currently holds EYE.AX.
No tracked institution reports a position in EYE.AX as of their last filing.
No one on the platform has traded EYE.AX yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 19.1% | 21.1% | ||||
| Profit Margin % | -12.4% | -45.4% | -36.3% | |||
| Free Cash Flow Margin % | -9.6% | -37.7% | -32.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $42M | +22.4% | $-0.01 | $-0.01–$-0.01 | — | 1 |
| 2028 | $51M | +21.1% | $0.01 | $0.01–$0.01 | — | 1 |
| 2029 | $62M | +21.1% | $0.00 | $0.00–$0.00 | — | 0 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 0 of the last 2 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-02-24 | $-0.01 | $-0.01 | -136.0% |
| 2025-02-22 | $-0.01 | $-0.02 | -249.2% |
| +10.64% |
| $30M |
| — |
| HMD.AXHeraMED Limited | $0.03 | +0.00% | $38M | — |
| IIQ.AXINOVIQ Ltd | $0.17 | +0.00% | $24M | — |
Source: Financial Modeling Prep · peers by sector/industry